sk&f-110679 and ipamorelin

sk&f-110679 has been researched along with ipamorelin* in 2 studies

Other Studies

2 other study(ies) available for sk&f-110679 and ipamorelin

ArticleYear
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
    Journal of medicinal chemistry, 1998, Sep-10, Volume: 41, Issue:19

    A new series of GH secretagogues derived from ipamorelin is described. In an attempt to obtain oral bioavailability, by reducing the size and the number of potential hydrogen-bonding sites of the compounds, a strategy using the peptidomimetic fragment 3-(aminomethyl)benzoic acid and sequential backbone N-methylations was applied. Several compounds from this series release GH with high in vitro potency and efficacy in a rat pituitary cell assay and high in vivo potency and efficacy in anesthetized rats. The tetrapeptide NNC 26-0235 (3-(aminomethyl)benzoyl-D-2Nal-N-Me-D-Phe-Lys-NH2) shows, following iv administration, comparable in vivo potency to ipamorelin, GHRP-2, and GHRP-6 with an ED50 in swine at 2 nmol/kg. NNC 26-0235 demonstrated a 10% oral bioavailability in dogs, and NNC 26-0235 and ipamorelin were able to increase basal GH level by more than 10-fold after oral administration of a dose of 1.8 and 2.7 mg/kg, respectively. The tripeptide NNC 26-0323 (3-(aminomethyl)benzoic acid-N-Me-D-2Nal-N-Me-D-Phe-ol) which showed moderate in vitro potency but lacked in vivo potency demonstrated a 20% oral bioavailability in rats.

    Topics: Administration, Oral; Animals; Biological Availability; Dogs; Female; Growth Hormone; Hormones; In Vitro Techniques; Injections, Intravenous; Magnetic Resonance Spectroscopy; Male; Molecular Mimicry; Oligopeptides; Pituitary Gland; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Swine

1998
Novel orally active growth hormone secretagogues.
    Journal of medicinal chemistry, 1998, Sep-10, Volume: 41, Issue:19

    A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding potential by incorporation of backbone isosters while retaining in vivo potency in swine. A rat pituitary assay was used for screening of all compounds and to evaluate which compounds should be tested further for in vivo potency in swine and oral bioavailability, fpo, in dogs. Most of the tested compounds had fpo in the range of 10-55%. In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound.

    Topics: Administration, Oral; Animals; Biological Availability; Dogs; Drug Evaluation, Preclinical; Female; Growth Hormone; Hormones; Injections, Intravenous; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Molecular Mimicry; Oligopeptides; Pituitary Gland; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Swine

1998